VectivBio (VECT) Stock Forecast, Price Target & Predictions
VECT Stock Forecast
VectivBio stock forecast is as follows: an average price target of $18.00 (represents a 6.82% upside from VECT’s last price of $16.85) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
VECT Price Target
The average price target for VectivBio (VECT) is $18.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $18.00 to $18.00. This represents a potential 6.82% upside from VECT's last price of $16.85.
VECT Analyst Ratings
According to 3 Wall Street analysts, VectivBio's rating consensus is 'Buy'. The analyst rating breakdown for VECT stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
VectivBio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 13, 2022 | - | Jefferies | $18.00 | $8.37 | 115.05% | 6.82% |
The latest VectivBio stock forecast, released on Dec 13, 2022 by Jefferies company, set a price target of $18.00, which represents a 115.05% increase from the stock price at the time of the forecast ($8.37), and a 6.82% increase from VECT last price ($16.85).
VectivBio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $16.85 | $16.85 | $16.85 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of VectivBio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to VectivBio's last price of $16.85. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Apr 20, 2023 | Piper Sandler | Overweight | Overweight | Hold |
| Dec 13, 2022 | Jefferies | - | Buy | Initialise |
| Sep 30, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 01, 2022 | Piper Sandler | - | Overweight | Initialise |
| Apr 26, 2022 | Zacks Investment Research | - | Hold | Upgrade |
VectivBio's last stock rating was published by Piper Sandler on Apr 20, 2023. The company gave VECT a "Overweight" rating, the same as its previous rate.
VectivBio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.63 | $70.00 | 11011.11% | Buy |
| ELEV | Elevation Oncology | $0.52 | $9.00 | 1630.77% | Buy |
| CNSP | CNS Pharmaceuticals | $0.11 | $0.50 | 354.55% | - |
| IMMX | Immix Biopharma | $1.58 | $7.00 | 343.04% | Buy |
| ZURA | Zura Bio | $4.37 | $5.00 | 14.42% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| EFTR | eFFECTOR Therapeutics | - | $5.50 | - | Buy |
VECT Forecast FAQ
Is VectivBio a good buy?
Yes, according to 3 Wall Street analysts, VectivBio (VECT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of VECT's total ratings.
What is VECT's price target?
VectivBio (VECT) average price target is $18 with a range of $18 to $18, implying a 6.82% from its last price of $16.85. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will VectivBio stock go up soon?
According to Wall Street analysts' prediction for VECT stock, the company can go up by 6.82% (from the last price of $16.85 to the average price target of $18), up by 6.82% based on the highest stock price target, and up by 6.82% based on the lowest stock price target.
Can VectivBio stock reach $30?
VECT's average twelve months analyst stock price target of $18 does not support the claim that VectivBio can reach $30 in the near future.